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trial (9). In HPS, no significant differences were found in cognitive
function or diagnosis of dementia between treatment groups
during this 5-year study with simvastatin. The PROSPER study
also specifically and prospectively addressed cognitive function,
including dementia, in its study population of patients aged 70 to
82 years (average 75 years) who demonstrated no evidence of
cognitive dysfunction at study entry, and found no effect of
pravastatin treatment on this domain during a 3-year trial (10).
Based on these two large-scale prospectively designed investiga-
tions, we can conclude that statin therapy does not appear to have
any beneficial or adverse effect on cognitive function assessed over
a 3 to 5-year period. Conceivably, a longer follow-up time may be
needed to detect a significant impact on dementia (11).
Most recently, because of the considerable attention given to
this topic by the lay media, many patients have been concerned
about statins actually causing memory loss and cognitive impair-
ment. Although this idea is mostly based on isolated case reports
without causality being established (12,13), the media attention
given to this topic has led to numerous phone calls to physicians’
offices as well as some patients stopping their statins. Although
these reports raise the possibility that statins, in rare cases, may be
associated with cognitive impairment, this is not supported by data
in over 30,000 patients in the two large-scale prospective studies
(9,10).
Further studies are needed before routinely adjusting therapeu-
tic targets for LDL in patients without ACS especially to targeted
LDL levels between 50 to 70 mg/dl, and long-term studies are still
required to better assess the clinical impact of statins on cognitive
function.
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REPLY
Since our study appeared in JACC (1), an update to the National
Cholesterol Education Program (NCEP) ATP III Guidelines
drafted by a panel of lipid experts (2) concurred that lower is in fact
better, and called for aggressively reducing low-density lipoprotein
(LDL) cholesterol to 70 mg/dl in high-risk patients. We
disagree with Drs. Lavie and Milani that this more aggressive
LDL target should be applied only to patients recovering from an
acute coronary syndrome. A consistent body of evidence shows a
close relationship between on-treatment LDL (extending to 70
mg/dl and below) and risk of cardiovascular events in both primary
and secondary prevention. Another large, randomized, placebo-
controlled trial, the Collaborative Atorvastatin Diabetes Study
(CARDS), has been presented since our study was published (3).
This trial randomized 2,838 patients with type-2 diabetes, but
with no documented atherosclerotic vascular disease, to either
atorvastatin 10 mg or placebo. Atorvastatin lowered the LDL
cholesterol, which was only 119 mg/dl before treatment, to 73
mg/dl. The CARDS trial was halted early owing to a 37%
reduction in major cardiovascular events in the atorvastatin group.
We would agree that the benefits of statins in reducing the
incidence of Alzheimer’s disease is more speculative at the present
time. Dementia is usually a heterogeneous disorder representing a
mixture between the neurodegenerative disease processes and
microvascular and large-vessel disease related to atherosclerosis
and endothelial dysfunction. Virtually all of the risk factors for
Alzheimer’s disease (e.g., hypertension, insulin resistance, diabetes,
smoking, hypercholesterolemia, and age) are also risks for athero-
sclerosis and microangiopathy (4). Trial data clearly demonstrate
treatment of hypertension reduces the incidence of dementia.
Case-control studies consistently show an association between
statin use and reduced incidence of Alzheimer’s disease (3).
Although the PROSPER trial did not show benefit for pravastatin
in reducing dementia in elderly patients, the trial lasted only 3
years, and the reduction in LDL was modest. Long-term random-
ized trials using potent statins to achieve and maintain LDL
cholesterols under 70 mg/dl will be required to definitively answer
the question regarding the ability of statins to prevent Alzheimer’s
disease.
Conversely, the ability of statins to reduce stroke risk is well
documented. The CARDS trial found atorvastatin reduced the
incidence of stroke in diabetic patients by 48% (3). A recent
meta-analysis of randomized controlled statin trials showed that
for every 5 years of treatment, the relative risk of stroke decreases
proportionately to LDL reduction, with atorvastatin reducing
stroke by 41% over 5 years, simvastatin up to 34%, and pravastatin
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by 31% (5). Because stroke is a major cause of dementia, statins
must be considered potentially valuable agents for preventing
cognitive decline in patients with risk factors for atherosclerosis or
dementia.
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Does Inhaled Nitric Oxide Support the
Hemodynamic of Spontaneous Breathing
Patients With Cardiogenic Shock Related to
Right Ventricular Myocardial Infarction?
We read with great interest the echocardiographic study published
by Inglessis et al. (1) concerning hemodynamic effects of inhaled
nitric oxide (NO) in right ventricular myocardial infarction
(RVMI) and cardiogenic shock (CS). They found that inhaled NO
results in acute hemodynamic improvement when administered to
patients with RVMI and CS.
We have a major concern with these results. Indeed, although
10 of 13 patients were under positive pressure ventilation, the
investigators leave the reader with the feeling that inhaled NO
results in significant hemodynamic improvement and a reduction
of right to left shunting when administered to all types of patients.
In our opinion, we may expect that the observed NO effect
could not be shown in spontaneous breathing patients. Indeed, as
stated by the researchers, breathing NO is thought to increase
pulmonary venous return and left ventricular filling pressure when
cardiac output is decreased (2). Because positive pressure ventila-
tion acts as a circulatory pump (3) and decreases left ventricular
transmural pressure, acute left ventricular failure may occur when
the lungs are not mechanically assisted.
In this setting, we suggest to Inglessis et al. (1) not to extend
their conclusions regarding the hemodynamic inhaled NO effects
to spontaneous ventilated patients with acute RVMI and CS.
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We thank Dr. Bendjelid for his interest in our work (1). We agree
that the majority of our patients were studied while undergoing
positive pressure ventilation. As only three patients in our study
population did not require mechanical ventilation, our ability to
extrapolate our results to patients with right ventricular myocardial
infarction (RVMI) not receiving mechanical ventilation is limited.
Nonetheless, there was no difference in the improvement in cardiac
index observed between those patients breathing nitric oxide (NO)
who were mechanically ventilated and those who were not.
Dr. Bendjelid also raises the concern that positive pressure
ventilation may act to prevent the development of acute left
ventricular (LV) failure that may occur during NO inhalation, and
that LV failure may arise in nonventilated patients. Left ventricular
filling pressures have been found to increase during NO inhalation
in patients with severe LV systolic dysfunction (2,3). The RVMI
patients in our study had primarily RV dysfunction, and the degree
of LV dysfunction was not as severe as in those patients in whom
the pulmonary capillary wedge pressure (PCWP) has been re-
ported to increase during NO inhalation. Furthermore, we ex-
cluded patients with a PCWP 25 mm Hg from study. In the
three nonventilated RVMI patients in our study, we did not
observe an increase in their PCWP while they were breathing NO
for 10 min.
In future studies of the effects of sustained NO inhalation in
RVMI patients, it will be important to observe the hemodynamic
effects of this agent in patients who receive positive pressure
ventilation as well as those who do not. Patients with severe LV
systolic function should be monitored carefully during chronic NO
inhalation because of the possibility of their developing pulmonary
venous hypertension.
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